AC
REGN icon

ASB Consultores’s Regeneron Pharmaceuticals REGN Stock Holding History

ASB Consultores’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-462
Closed -$243K – 120
2025
Q2 		$243K Buy
462
+107
+30% +$59.7K 0.16% 120
2025
Q1 		$225K Sell
355
-155
-30% -$107K 0.15% 105
2024
Q4 		$363K Sell
510
-2
-0.4% -$1.68K 0.15% 115
2024
Q3 		$538K Sell
512
-64
-11% -$71.2K 0.21% 73
2024
Q2 		$605K Sell
576
-224
-28% -$217K 0.22% 61
2024
Q1 		$770K Buy
+800
New +$761K 0.2% 74
2023
Q4 		– Sell
-255
Closed -$210K – 151
2023
Q3 		$210K Sell
255
-146
-36% -$115K 0.08% 131
2023
Q2 		$288K Sell
401
-153
-28% -$118K 0.14% 137
2023
Q1 		$455K Buy
554
+175
+46% +$132K 0.18% 81
2022
Q4 		$273K Buy
+379
New +$280K 0.11% 141
2022
Q2 		– Sell
-360
Closed -$251K – 223
2022
Q1 		$251K Buy
+360
New +$228K 0.11% 175

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ASB Consultores's REGN Position: Q3 2025 in Review

ASB Consultores sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 462 shares — an estimated $243K sold.

ASB Consultores first reported a position in REGN in Q1 2022 and held it in 11 quarters. The position peaked at $770K in Q1 2024. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • ASB Consultores reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • ASB Consultores sold 462 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $243K.
  • ASB Consultores first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • ASB Consultores's Regeneron Pharmaceuticals position peaked at $770K in Q1 2024.
  • 1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on ASB Consultores's 13F filing for Q3 2025, filed 4 Nov 2025.